it stands for data safety monitoring board. They unblind the data and assess the safety of the drug. XanADu has 3 DSMB assessments over phase 2. The first was in may, where they tested EFFICACY and safety of the first 50 patients, the second was around late august or early september, this assessed around 124 (a guess) patients for just safety, which came back all clear. And the last one was meant to be in december, but will instead be any day now. Once the final DSMB is announced, and it is all clear, then safety will no longer be burdening our minds in anticipation for the results. 186/186 patients will most likely be assessed based on the previous DSMB announcements which incorporated both completed patients and patients undergoing treatment.
ACW Price at posting:
5.7¢ Sentiment: Buy Disclosure: Held
